VIR 101

Drug Profile

VIR 101

Latest Information Update: 09 Jan 2004

Price : $50

At a glance

  • Originator Aventis
  • Developer Virogen
  • Class Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Hepatitis B; HIV infections

Most Recent Events

  • 09 Jan 2004 No development reported - Preclinical for HIV infections treatment in United Kingdom (unspecified route)
  • 09 Jan 2004 No development reported - Preclinical for Hepatitis B in United Kingdom (unspecified route)
  • 02 May 2001 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top